ROIVANT SCIENCES LTD.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

US GAAP

Reporting scope

Consolidated group

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

Group structure

1. ROIVANT SCIENCES LTD. · parent
   1. Genevant Sciences Holdings Limited
   2. Hemavant Sciences Holdings Limited
   3. Immunovant Sciences Holdings Limited
   4. Roivant Sciences Holdings Limited

Significant events

• “In December 2023, the Company sold its entire equity interest in its majority-owned subsidiary Telavant Holdings, Inc. ("Telavant"). At closing, the Company received approximately $5.2 billion in cash.”
• “In September 2024, the Company's subsidiary, Dermavant Sciences Ltd. ("Dermavant"), entered into an Agreement and Plan of Merger... The Dermavant Transaction was completed in October 2024.”
• “In July 2023, Pulmovant Inc. ("Pulmovant"), a wholly-owned subsidiary of the Company, in-licensed certain intellectual property rights in exchange for a $14.0 million upfront cash payment.”
• “In July 2023, VantAI Holdings, Inc. ("VantAl"), a wholly-owned subsidiary of the Company, completed a transaction pursuant to which SK, Inc. ("SK") contributed $6.0 million to VantAI in exchange for preferred shares in VantAI.”
• “In August 2023, the Company and SK Biopharmaceuticals Co., Ltd. ("SK Bio"), a subsidiary of SK, completed a transaction pursuant to which SK Bio purchased all of the Company's shares in Proteovant Sciences, Inc. ("Proteovant") in exchange for $47.5 million.”
• “In April 2024, pursuant to the share repurchase program, the Company entered into a share repurchase agreement with Sumitomo and repurchased all 71,251,083 common shares held by Sumitomo at a purchase price per share of $9.10, for an aggregate purchase price of approximately $648.4 million.”
• “In September 2023, the Company entered into common share purchase and sale agreements with certain institutional investors, pursuant to which the Company sold an aggregate of 19,600,685 of its common shares at a price of $10.21 per share.”
• “In January 2025, Immunovant entered into a share purchase agreement pursuant to which Immunovant issued 22,500,000 shares of its common stock (including 16,845,010 shares of common stock purchased by the Company) at a price of $20.00 per share in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the "IMVT PIPE").”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

17

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -11.2%

  £24,249,815 → £21,536,694

  lowest in 3 filed years

• Cash

  -48.6%

  £135,407,709 → £69,647,146

• Net assets

  -19.6%

  £4,780,229,059 → £3,845,217,198

• Employees

  —

  Not reported

• Operating profit

  -122.3%

  £3,333,604,151 → -£743,731,653

  lowest in 3 filed years

• Profit before tax

  -114.9%

  £3,386,105,263 → -£505,255,745

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers